GB974625A - Injectable pharmaceutical emulsion vehicles - Google Patents

Injectable pharmaceutical emulsion vehicles

Info

Publication number
GB974625A
GB974625A GB29950/61A GB2995061A GB974625A GB 974625 A GB974625 A GB 974625A GB 29950/61 A GB29950/61 A GB 29950/61A GB 2995061 A GB2995061 A GB 2995061A GB 974625 A GB974625 A GB 974625A
Authority
GB
United Kingdom
Prior art keywords
viruses
influenza
derived
pollens
venoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB29950/61A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB974625A publication Critical patent/GB974625A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A stable water-in-oil emulsion suitable for use as pharmaceutical vehicle, e.g. for injection comprises by volume; about 25 to 90% vegetable oil, 2.5 to 25% sorbitan trioleate, 1.25 to 2.5% aluminium monostearate and/or aluminium hydroxide and water. The emulsion is of particular use as a vehicle for immunological substances, e.g. antigens and allergens derived from bacteria, rickettsia, viruses, pollens, dusts, danders and extracts thereof and poisons or venoms from insects and reptiles, examples of these given including antigens derived from H. pertussis, Leptospira panona and icterohaemorrhagiae, S. typhosa, S. paratyphi A and B, C. diphtheriae, C. tetani, C. botulinum, C. perfringens, C. feseri, B. anthracis, P. pestis, P. multocida, V. cholerae, polio, adeno, para-influenza, measles, mumps, respiratory syncytial, influenza, shipping fever viruses, encephalomyelitis, Hog cholera, Newcastle disease, Fowl pox, Rabies, Feline and Canine distemper viruses, epidemic and endemic typhus rickettsiae, spider and snake venoms, and allergens derived from ragweed, house dust, pollen extracts and grass pollens, the active material being present in the aqueous phase of the emulsions.
GB29950/61A 1960-09-06 1961-08-18 Injectable pharmaceutical emulsion vehicles Expired GB974625A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5393160A 1960-09-06 1960-09-06

Publications (1)

Publication Number Publication Date
GB974625A true GB974625A (en) 1964-11-11

Family

ID=21987534

Family Applications (1)

Application Number Title Priority Date Filing Date
GB29950/61A Expired GB974625A (en) 1960-09-06 1961-08-18 Injectable pharmaceutical emulsion vehicles

Country Status (4)

Country Link
CH (1) CH413237A (en)
FR (1) FR4690M (en)
GB (1) GB974625A (en)
NL (1) NL269002A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
FR2443873A1 (en) * 1978-12-14 1980-07-11 Kao Corp NOVEL EMULSIFYING COMPOSITION FOR THE PRODUCTION AND STABILIZATION OF WATER-IN-OIL EMULSIONS
GB2170708A (en) * 1985-02-10 1986-08-13 Israel State Injectable vaccine system
USRE32393E (en) * 1967-09-01 1987-04-07 Kabivitrum Ab Composition for enhancing the administration of pharmacologically active agents

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH662944A5 (en) * 1984-10-18 1987-11-13 Pier Luigi Prof Dr Luisi PROCEDURE FOR THE PREPARATION OF BIOCOMPATIBLE REVERSE MICROCOMPATIBLES AND THEIR USE.
DE3446515A1 (en) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg OIL ADJUVED VACCINE AND METHOD FOR THE PRODUCTION THEREOF
FR2702374B1 (en) * 1993-03-08 1995-04-14 Rhone Merieux Water-in-oil fluid vaccine emulsions containing a metabolizable oil.
FR2702373B1 (en) * 1993-03-08 1996-06-07 Rhone Merieux Water-in-oil fluid vaccine emulsions containing a metabolizable oil.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32393E (en) * 1967-09-01 1987-04-07 Kabivitrum Ab Composition for enhancing the administration of pharmacologically active agents
US4158054A (en) 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
FR2443873A1 (en) * 1978-12-14 1980-07-11 Kao Corp NOVEL EMULSIFYING COMPOSITION FOR THE PRODUCTION AND STABILIZATION OF WATER-IN-OIL EMULSIONS
GB2170708A (en) * 1985-02-10 1986-08-13 Israel State Injectable vaccine system

Also Published As

Publication number Publication date
NL269002A (en)
FR4690M (en) 1966-12-26
CH413237A (en) 1966-05-15

Similar Documents

Publication Publication Date Title
US4069313A (en) Water-in-oil adjuvant composition
GB974625A (en) Injectable pharmaceutical emulsion vehicles
US3983228A (en) Water-in-oil adjuvant composition
US4229441A (en) Immunologic adjuvant
DE60036952T2 (en) INFLUENZA VIRUS VACCINE COMPOSITION FOR NASAL APPLICATION
KR100373593B1 (en) Vaccine composition
Thapar et al. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM)
JP2003509451A5 (en)
Masurel Serological characteristics of a” new” serotype of influenza A virus: the Hong Kong strain
ATE322289T1 (en) INTERLEUKIN-12 AS AN ADJUVANT FOR PARAMYOXVIRIDAE VACCINES
CN107469075A (en) A kind of high dose tetravalence Inflenza vaccine composition
DE2945788C2 (en)
FENTERS et al. Serotypic relationships among rhinoviruses
JPS5939831A (en) Inactivated vaccine of influenzal virus for pig
GB953992A (en) Vaccine products and method of preparing same
Hennessy et al. Studies on vaccination of infants against influenza with influenza hemagglutinin
US2720484A (en) Process for separation of viral substances from animal tissues
JP4282804B2 (en) Adjuvant composition
Kucera et al. Studies on the antigenicity of an inactivated, aluminum hydroxide adjuvant equine influenza vaccine.
JPS6242890B2 (en)
Hanson et al. The antiviral activity of Newcastle disease immune sera
Leroy et al. Fast track development of a Zika vaccine based on measles vector–ZIKAVAX
Zotova et al. ANALYSIS OF INTERDEPENDENCE OF INDICATORS OF LOCAL IMMUNITY DEPENDING ON THE DURATION OF HPV INFECTION
Schieble et al. Rhinoviruses: an antigenic study of the prototype virus strains
Lien et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge (preprint)